Redcare Pharmacy stock costs EUR 73.35 with P/ E of -35.5
Published on 10/08/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Redcare Pharmacy stock was at EUR 73.35 at Lang & Schwarz after the Xetra close on October 8, 2026.
- The finance quote showed a P/E ratio of -35.5 and a market capitalization of EUR 1.5 billion.
- The stock's 52-week range was EUR 30.20 to EUR 90.05, while third-quarter results are scheduled for October 29, 2026.
- Berenberg raised its Redcare Pharmacy price target from EUR 94.00 to EUR 102.00 and kept its Buy rating.
Redcare Pharmacy (ISIN NL0012044747) was at EUR 73.35 at Lang & Schwarz after the Xetra close on October 8, 2026, while its P/E ratio stood at -35.5. The price sits EUR 16.70 below the 52-week high of EUR 90.05, placing the valuation question ahead of the next scheduled report.
Stock remains below yearly high
The 52-week range runs from EUR 30.20 to EUR 90.05 as of October 8, 2026. At EUR 73.35, the stock was 18.55 percent below the upper end of that range, calculated from the same-day finance quote.
Redcare Pharmacy had a market capitalization of EUR 1.5 billion on October 8, 2026. Its reported P/E ratio was -35.5, while the trailing dividend yield was 0.00 percent, so earnings and growth expectations remain more relevant valuation markers than income distribution.
Analyst target reaches EUR 102
BÖRSE ONLINE reported on October 7, 2026 that Berenberg raised its target for Redcare Pharmacy from EUR 94.00 to EUR 102.00 and kept its Buy rating. The new target lies 39.18 percent above EUR 73.35, using both values in euros.
The same report named analyst Gerhard Orgonas and linked the more constructive view to customer experiences in prescription medicines. That assessment gives the target price a concrete operating context, although the current valuation still reflects a negative trailing P/E ratio.
Comparison with peers
Redcare Pharmacy: minus 1.6 percent, P/E -35.5, EUR 1.5 billion
DocMorris: plus 2.5 percent, P/E -8.7, CHF 669.8 million
CVS Health: minus 0.9 percent, P/E 23.1, USD 111.2 billion
Results date is October 29
Redcare Pharmacy lists its third-quarter 2026 interim statement for October 29, 2026. The date is the next scheduled reporting point for investors assessing whether prescription-drug growth can support the company's valuation.
FinanzNachrichten identifies Redcare Pharmacy's listing as Xetra with ticker RDC and confirms SDAX membership. Those static market details frame the euro quote for German investors.
Quote and market details
At Lang & Schwarz, the stock stood at EUR 73.35 on October 8, 2026 at 5:01 p.m. CEST, after the Xetra close. The bid was EUR 73.20 and the ask was EUR 73.50.
The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy stock facts
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Ticker: RDC
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 8, 2026, 5:01 p.m. CEST): EUR 73.35
- Market capitalization: EUR 1.5 billion (as of October 8, 2026)
- 52-week range: EUR 30.20-90.05 (as of October 8, 2026)
- Sector / Industry: Consumer Discretionary / Internet and Direct Marketing Retail
- Index membership: SDAX
- Next earnings date: October 29, 2026
Market context: Market report AEX.
